China: Cell and Gene Therapy mRNA Drugs China Launches its Largest Commercial GMP Plasmid Manufacturing Plant

From Ahlam Rais

Genscript Probio has inaugurated its mega facility which is claimed to be China’s largest commercial GMP plasmid manufacturing plant. The plant will enable the firm to offer customers across the globe a one-stop service for plasmids. The move is expected to speed up the innovation and development of high-quality cell and gene therapy mRNA drugs.

Related Companies

Genscript Probio’s largest commercial GMP plasmid manufacturing facility in China inaugurated in Zhenjiang, Jiangsu Province.
Genscript Probio’s largest commercial GMP plasmid manufacturing facility in China inaugurated in Zhenjiang, Jiangsu Province.
(Source: Business Wire)

Nanjing/China – Genscript Probio recently announced the inauguration of China's largest commercial GMP plasmid manufacturing facility during a ceremony at the site in Zhenjiang, Jiangsu Province. The 6,400-square-meter manufacturing plant enables the firm to offer global customers a one-stop service for plasmids - from preclinical study (IIT), to investigational new drug (IND) filing, to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

As Genscript Probio's second GMP plasmid manufacturing facility, the plant more than doubles the company's production capacity and strengthens its position as a leading CDMO. It enables the company to offer services including off-the-shelf LentiHelp plasmids, Pro grade plasmids for preclinical development, plasmids CMC study for IND filing, clinical GMP plasmids for early clinical trials, and cGMP plasmids for late-phase and commercialization.

The facility also expands the company’s operations, which already included the largest commercial GMP plasmid manufacturing facility in China.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:47886826)